These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29678127)

  • 1. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective.
    Nuijten M; Dainelli L; Rasouli B; Araujo Torres K; Perugini M; Marczewska A
    Diabetes Metab Syndr Obes; 2021; 14():3147-3160. PubMed ID: 34267531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
    Olivieri AV; Muratov S; Larsen S; Luckevich M; Chan K; Lamotte M; Lau DCW
    Int J Obes (Lond); 2024 May; 48(5):683-693. PubMed ID: 38291203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
    Kim N; Wang J; Burudpakdee C; Song Y; Ramasamy A; Xie Y; Sun R; Kumar N; Wu EQ; Sullivan SD
    J Manag Care Spec Pharm; 2022 Jul; 28(7):740-752. PubMed ID: 35737858
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium.
    Borisenko O; Lukyanov V; Debergh I; Dillemans B
    J Med Econ; 2018 Apr; 21(4):365-373. PubMed ID: 29271279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and Economic Impacts of the National Menu Calorie Labeling Law in the United States: A Microsimulation Study.
    Liu J; Mozaffarian D; Sy S; Lee Y; Wilde PE; Abrahams-Gessel S; Gaziano T; Micha R;
    Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006313. PubMed ID: 32493057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.
    Wentworth JM; Dalziel KM; O'Brien PE; Burton P; Shaba F; Clarke PM; Laiteerapong N; Brown WA
    J Diabetes Complications; 2017 Jul; 31(7):1139-1144. PubMed ID: 28462893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of lifestyle intervention in obese infertile women.
    van Oers AM; Mutsaerts MAQ; Burggraaff JM; Kuchenbecker WKH; Perquin DAM; Koks CAM; van Golde R; Kaaijk EM; Schierbeek JM; Klijn NF; van Kasteren YM; Land JA; Mol BWJ; Hoek A; Groen H;
    Hum Reprod; 2017 Jul; 32(7):1418-1426. PubMed ID: 28486704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling.
    Borisenko O; Mann O; Duprée A
    BMC Surg; 2017 Aug; 17(1):87. PubMed ID: 28774333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet.
    Rognoni C; Armeni P; Tarricone R; Donin G
    Clin Ther; 2020 Jan; 42(1):60-75.e7. PubMed ID: 31959413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme.
    Xin Y; Davies A; Briggs A; McCombie L; Messow CM; Grieve E; Leslie WS; Taylor R; Lean MEJ
    Diabetologia; 2020 Oct; 63(10):2112-2122. PubMed ID: 32776237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.
    Alshahawey M; Ghazy M; El Morshedy M; El Said NO
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3365-3374. PubMed ID: 38766793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts.
    Griffiths UK; Anigbogu B; Nanchahal K
    Appl Health Econ Health Policy; 2012 May; 10(3):145-62. PubMed ID: 22439628
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.